NO753230L - - Google Patents
Info
- Publication number
- NO753230L NO753230L NO753230A NO753230A NO753230L NO 753230 L NO753230 L NO 753230L NO 753230 A NO753230 A NO 753230A NO 753230 A NO753230 A NO 753230A NO 753230 L NO753230 L NO 753230L
- Authority
- NO
- Norway
- Prior art keywords
- units
- mol
- active substance
- weight
- molding compound
- Prior art date
Links
- 239000013543 active substance Substances 0.000 claims description 49
- 229920001296 polysiloxane Polymers 0.000 claims description 43
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 40
- 238000000465 moulding Methods 0.000 claims description 37
- 150000001875 compounds Chemical class 0.000 claims description 31
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 22
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 20
- 229910052697 platinum Inorganic materials 0.000 claims description 17
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 16
- -1 polydimethylsiloxane Polymers 0.000 claims description 14
- 239000012876 carrier material Substances 0.000 claims description 12
- 229920001577 copolymer Polymers 0.000 claims description 9
- 239000003937 drug carrier Substances 0.000 claims description 8
- 238000004132 cross linking Methods 0.000 claims description 6
- 230000007774 longterm Effects 0.000 claims description 4
- 230000003197 catalytic effect Effects 0.000 claims description 3
- 229920002554 vinyl polymer Polymers 0.000 claims description 3
- 239000012907 medicinal substance Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 description 26
- 229940079593 drug Drugs 0.000 description 22
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 21
- 239000000203 mixture Substances 0.000 description 21
- 239000000725 suspension Substances 0.000 description 20
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 19
- 239000000969 carrier Substances 0.000 description 17
- IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 description 13
- 238000010438 heat treatment Methods 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 229960001652 norethindrone acetate Drugs 0.000 description 12
- 229920001971 elastomer Polymers 0.000 description 11
- 239000000806 elastomer Substances 0.000 description 11
- 229960004400 levonorgestrel Drugs 0.000 description 11
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 239000003054 catalyst Substances 0.000 description 9
- 229920002379 silicone rubber Polymers 0.000 description 9
- 238000004073 vulcanization Methods 0.000 description 9
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- 239000010949 copper Substances 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 7
- 229910052802 copper Inorganic materials 0.000 description 7
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 6
- JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 description 6
- 239000000377 silicon dioxide Substances 0.000 description 6
- 235000012239 silicon dioxide Nutrition 0.000 description 6
- 239000004753 textile Substances 0.000 description 6
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 5
- 229920000742 Cotton Polymers 0.000 description 5
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 5
- 239000008186 active pharmaceutical agent Substances 0.000 description 5
- 229960002568 ethinylestradiol Drugs 0.000 description 5
- 239000011888 foil Substances 0.000 description 5
- 238000002513 implantation Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 150000003058 platinum compounds Chemical class 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 229940126062 Compound A Drugs 0.000 description 4
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 229940126601 medicinal product Drugs 0.000 description 4
- IMSSROKUHAOUJS-MJCUULBUSA-N mestranol Chemical compound C1C[C@]2(C)[C@@](C#C)(O)CC[C@H]2[C@@H]2CCC3=CC(OC)=CC=C3[C@H]21 IMSSROKUHAOUJS-MJCUULBUSA-N 0.000 description 4
- 229960001390 mestranol Drugs 0.000 description 4
- 239000004971 Cross linker Substances 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229940045985 antineoplastic platinum compound Drugs 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 238000011866 long-term treatment Methods 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 229940053934 norethindrone Drugs 0.000 description 3
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 3
- 239000004945 silicone rubber Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- NNJPGOLRFBJNIW-HNNXBMFYSA-N (-)-demecolcine Chemical compound C1=C(OC)C(=O)C=C2[C@@H](NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-HNNXBMFYSA-N 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- 229910002621 H2PtCl6 Inorganic materials 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 229930182833 estradiol Natural products 0.000 description 2
- 229960005309 estradiol Drugs 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 229960004296 megestrol acetate Drugs 0.000 description 2
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 2
- 125000005375 organosiloxane group Chemical group 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- DXPPIEDUBFUSEZ-UHFFFAOYSA-N 6-methylheptyl prop-2-enoate Chemical compound CC(C)CCCCCOC(=O)C=C DXPPIEDUBFUSEZ-UHFFFAOYSA-N 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- LVHOURKCKUYIGK-RGUJTQARSA-N Dimethisterone Chemical compound C1([C@@H](C)C2)=CC(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C#CC)(O)[C@@]2(C)CC1 LVHOURKCKUYIGK-RGUJTQARSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- YNVGQYHLRCDXFQ-XGXHKTLJSA-N Lynestrenol Chemical compound C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 YNVGQYHLRCDXFQ-XGXHKTLJSA-N 0.000 description 1
- ICTXHFFSOAJUMG-SLHNCBLASA-N Norethynodrel Chemical compound C1CC(=O)CC2=C1[C@H]1CC[C@](C)([C@](CC3)(O)C#C)[C@@H]3[C@@H]1CC2 ICTXHFFSOAJUMG-SLHNCBLASA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 244000208734 Pisonia aculeata Species 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- IVFILROKUQKCPB-UHFFFAOYSA-N carbonyl dichloride;platinum Chemical compound [Pt].ClC(Cl)=O IVFILROKUQKCPB-UHFFFAOYSA-N 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 238000005238 degreasing Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 229950006690 dimethisterone Drugs 0.000 description 1
- 229920005645 diorganopolysiloxane polymer Polymers 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000816 effect on animals Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- CHNXZKVNWQUJIB-CEGNMAFCSA-N ethisterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 CHNXZKVNWQUJIB-CEGNMAFCSA-N 0.000 description 1
- 229960000445 ethisterone Drugs 0.000 description 1
- ONKUMRGIYFNPJW-KIEAKMPYSA-N ethynodiol diacetate Chemical compound C1C[C@]2(C)[C@@](C#C)(OC(C)=O)CC[C@H]2[C@@H]2CCC3=C[C@@H](OC(=O)C)CC[C@@H]3[C@H]21 ONKUMRGIYFNPJW-KIEAKMPYSA-N 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229960001207 micronized progesterone Drugs 0.000 description 1
- 239000012778 molding material Substances 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 229910000510 noble metal Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229960001858 norethynodrel Drugs 0.000 description 1
- YPVUHOBTCWJYNQ-SLHNCBLASA-N norgesterone Chemical compound C1CC(=O)CC2=C1[C@H]1CC[C@](C)([C@](CC3)(O)C=C)[C@@H]3[C@@H]1CC2 YPVUHOBTCWJYNQ-SLHNCBLASA-N 0.000 description 1
- 229950011191 norgesterone Drugs 0.000 description 1
- 229960002831 norgestrienone Drugs 0.000 description 1
- GVDMJXQHPUYPHP-FYQPLNBISA-N norgestrienone Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](C)([C@](CC3)(O)C#C)C=C3)C3=C21 GVDMJXQHPUYPHP-FYQPLNBISA-N 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229920006136 organohydrogenpolysiloxane Polymers 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 150000003057 platinum Chemical class 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000131 polyvinylidene Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- FLGJKPPXEKYCBY-AKCFYGDASA-N quingestanol acetate Chemical compound C([C@H]1[C@@H]2CC[C@@]([C@]2(CC[C@@H]1[C@H]1CC2)C)(OC(=O)C)C#C)C=C1C=C2OC1CCCC1 FLGJKPPXEKYCBY-AKCFYGDASA-N 0.000 description 1
- 229950009172 quingestanol acetate Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000009958 sewing Methods 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- QFJIELFEXWAVLU-UHFFFAOYSA-H tetrachloroplatinum(2+) dichloride Chemical compound Cl[Pt](Cl)(Cl)(Cl)(Cl)Cl QFJIELFEXWAVLU-UHFFFAOYSA-H 0.000 description 1
- KSBAEPSJVUENNK-UHFFFAOYSA-L tin(ii) 2-ethylhexanoate Chemical compound [Sn+2].CCCCC(CC)C([O-])=O.CCCCC(CC)C([O-])=O KSBAEPSJVUENNK-UHFFFAOYSA-L 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 239000002966 varnish Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A61K9/0039—Devices retained in the uterus for a prolonged period, e.g. intrauterine devices for contraception
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
- A61K9/2036—Silicones; Polysiloxanes
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Reproductive Health (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Materials For Medical Uses (AREA)
- Media Introduction/Drainage Providing Device (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19742445971 DE2445971A1 (de) | 1974-09-24 | 1974-09-24 | Arzneimittelwirkstofftraeger ii |
Publications (1)
Publication Number | Publication Date |
---|---|
NO753230L true NO753230L (da) | 1976-03-25 |
Family
ID=5926793
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO753230A NO753230L (da) | 1974-09-24 | 1975-09-23 |
Country Status (27)
Country | Link |
---|---|
US (1) | US4012497A (da) |
JP (1) | JPS5161618A (da) |
AT (1) | AT347588B (da) |
AU (1) | AU498204B2 (da) |
BE (1) | BE833762A (da) |
BG (1) | BG27880A3 (da) |
CA (1) | CA1049408A (da) |
CH (1) | CH624580A5 (da) |
DD (1) | DD122197A5 (da) |
DE (1) | DE2445971A1 (da) |
DK (1) | DK143384C (da) |
EG (1) | EG11859A (da) |
ES (1) | ES441203A1 (da) |
FI (1) | FI58871C (da) |
FR (1) | FR2285895A1 (da) |
GB (1) | GB1521505A (da) |
HU (1) | HU175675B (da) |
IE (1) | IE41717B1 (da) |
IL (1) | IL48100A (da) |
IN (1) | IN142359B (da) |
IT (1) | IT1042731B (da) |
NL (1) | NL7511244A (da) |
NO (1) | NO753230L (da) |
PL (1) | PL105375B1 (da) |
SE (1) | SE7510658L (da) |
SU (1) | SU605547A3 (da) |
ZA (1) | ZA756082B (da) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4155991A (en) * | 1974-10-18 | 1979-05-22 | Schering Aktiengesellschaft | Vaginal ring |
US4219016A (en) * | 1978-12-07 | 1980-08-26 | The Procter & Gamble Company | Vaginal contraceptive |
US4191741A (en) * | 1978-09-22 | 1980-03-04 | Eli Lilly And Company | Removable drug implant |
US4292965A (en) * | 1978-12-29 | 1981-10-06 | The Population Council, Inc. | Intravaginal ring |
US4200090A (en) * | 1979-01-15 | 1980-04-29 | The Procter & Gamble Company | Vaginal contraceptive and method of using |
US4264576A (en) * | 1979-06-28 | 1981-04-28 | Eli Lilly And Company | Contraceptive methods and compositions |
US4343788A (en) * | 1979-06-29 | 1982-08-10 | The Procter & Gamble Company | Antimicrobial polymer compositions |
US4479795A (en) * | 1979-06-29 | 1984-10-30 | The Procter & Gamble Company | Antimicrobial polymer compositions |
US4264575A (en) * | 1979-07-16 | 1981-04-28 | Eli Lilly And Company | Contraceptive methods and compositions |
US4264578A (en) * | 1979-07-16 | 1981-04-28 | Eli Lilly And Company | Contraceptive methods and compositions |
US4264577A (en) * | 1979-08-03 | 1981-04-28 | Eli Lilly And Company | Contraceptive methods and compositions |
US4341728A (en) * | 1979-12-20 | 1982-07-27 | The Population Council, Inc. | Method for making an IUD with shrinking of a medicated attachment onto a support |
US4304226A (en) * | 1980-03-03 | 1981-12-08 | The Procter & Gamble Company | Vaginal contraceptive |
AU538961B2 (en) * | 1980-06-09 | 1984-09-06 | Alex Harvey Industries Limited | Intra-vaginal device |
DE3040978A1 (de) * | 1980-10-28 | 1982-05-27 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Vaginalring |
EP0076068A3 (en) * | 1981-09-25 | 1985-05-15 | Beecham Group Plc | Intramammary veterinary compositions and method for their use |
NZ200564A (en) * | 1982-05-10 | 1987-03-06 | Ahi Operations Ltd | Device for slowly releasing chemicals into body cavities of animals |
US4435180A (en) | 1982-05-25 | 1984-03-06 | Alza Corporation | Elastomeric active agent delivery system and method of use |
US4563184A (en) * | 1983-10-17 | 1986-01-07 | Bernard Korol | Synthetic resin wound dressing and method of treatment using same |
FR2560768A1 (fr) * | 1984-03-07 | 1985-09-13 | Crb Virbac Sa | Dispositif a liberation programmee |
EP0214969A4 (en) * | 1984-04-19 | 1987-12-17 | Univ Queensland | CONTRACEPTIVE METHODS AND DISTRIBUTION SYSTEMS THEREFOR. |
US4673565A (en) * | 1985-05-03 | 1987-06-16 | E. I. Du Pont De Nemours And Company | Pharmaceutical compositions containing hollow fine tubular drug delivery systems |
NZ217844A (en) * | 1985-10-11 | 1989-10-27 | Sumitomo Pharma | A sustained release pharmaceutical composition containing silicone elastomer and an albumin |
US5560922A (en) * | 1986-05-30 | 1996-10-01 | Rutgers, The State University Of New Jersey | Transdermal absorption dosage unit using a polyacrylate adhesive polymer and process |
US5238679A (en) * | 1987-02-26 | 1993-08-24 | Rhone-Poulenc Chimie | Diorganopolysiloxane dosage forms for the controlled release of iodine values |
FR2611733B1 (fr) * | 1987-02-26 | 1989-06-16 | Rhone Poulenc Chimie | Composition a base de gomme diorganopolysiloxane contenant de l'iode pour le traitement des eaux |
FR2611734B1 (fr) * | 1987-02-26 | 1989-06-16 | Rhone Poulenc Chimie | Composition elastomere silicone polycondensation contenant de l'iode pour le traitement des eaux |
FR2611735B1 (fr) * | 1987-02-26 | 1989-06-16 | Rhone Poulenc Chimie | Composition elastomere silicone polyaddition contenant de l'iode pour le traitement de l'eau |
US4879304A (en) * | 1987-05-01 | 1989-11-07 | Angelini Pharmaceuticals Ltd. | Ophthalmic compositions and process for preparing |
HU197519B (en) * | 1987-06-22 | 1989-04-28 | Biogal Gyogyszergyar | Process for producing medicine form capable for penetrating through epidermis and suitable for intaking the agent through epidermis by kinetics of zero-grade |
DE3727180A1 (de) * | 1987-08-14 | 1989-02-23 | Wacker Chemie Gmbh | Waessrige silicondispersionen |
US4867968A (en) * | 1987-12-29 | 1989-09-19 | Florida-Kansas Health Care, Inc. | Elastomeric composition containing therapeutic agents and articles manufactured therefrom |
US5019378A (en) * | 1987-12-29 | 1991-05-28 | Cuno, Incorporated | Elastomeric composition containing therapeutic agents and articles manufactured therefrom |
US5019601A (en) * | 1987-12-29 | 1991-05-28 | Cuno, Incorporated | Elastomeric composition containing therapeutic agents and articles manufactured therefrom |
US4879294A (en) * | 1988-01-28 | 1989-11-07 | Angelini Pharmaceuticals Ltd. | Opthalmic composition |
US4906475A (en) * | 1988-02-16 | 1990-03-06 | Paco Pharmaceutical Services | Estradiol transdermal delivery system |
JP2590358B2 (ja) * | 1988-03-01 | 1997-03-12 | 正雄 五十嵐 | 子宮内膜症治療用の子宮内又は膣内投与製剤 |
DE3838815A1 (de) * | 1988-11-17 | 1990-05-23 | Hoechst Ag | Verfahren zum herstellen eines intravaginalen applikationssystems |
GB2252497B (en) * | 1991-02-04 | 1995-01-18 | Elsimar Metzker Coutinho | Pharmaceutical composition |
US5620499A (en) * | 1992-12-14 | 1997-04-15 | Farley; James J. | Chemical dispensing device and method |
US5505963A (en) * | 1993-04-07 | 1996-04-09 | Schwartz Pharma Ag | Slow release pharmaceutical preparation |
NZ510400A (en) * | 1998-09-10 | 2003-03-28 | Sumitomo Pharma | Sustained release preparation of lipophilic drugs in which the excessive initial drug release is suppressed and a sustained release is effected |
US6787531B1 (en) * | 1999-08-31 | 2004-09-07 | Schering Ag | Pharmaceutical composition for use as a contraceptive |
AU2003267309A1 (en) | 2000-11-16 | 2004-04-08 | Microspherix Llc | Flexible and/or elastic brachytherapy seed or strand |
CN1536986B (zh) * | 2001-03-27 | 2012-07-04 | 沃纳奇尔科特(爱尔兰)有限公司 | 用于抗微生物剂给药的阴道内药物递送装置 |
ES2388731T5 (es) * | 2002-03-27 | 2018-01-19 | Warner Chilcott (Ireland) Limited | Dispositivos de administración de fármacos mediante una matriz intravaginal |
ATE445393T1 (de) * | 2003-04-24 | 2009-10-15 | Jagotec Ag | Tablette mit gefärbtem kern |
WO2006026844A1 (en) * | 2004-09-09 | 2006-03-16 | Biolab Sanus Farmacêutica Ltda. | Hormone delayed release composition on the basis of polyorganosiloxanes or ethylene vinyl acetate resp. process for its manufacture |
US7862552B2 (en) * | 2005-05-09 | 2011-01-04 | Boston Scientific Scimed, Inc. | Medical devices for treating urological and uterine conditions |
DK2049123T4 (da) | 2006-08-03 | 2016-11-28 | Horizon Pharma Ag | Forsinket afgivelses-glucocorticoid-behandling af rheumatoid sygdom |
EP2293779A1 (en) * | 2008-04-24 | 2011-03-16 | Evestra, Inc. | Oral contraceptive dosage forms comprising a progestogen dispersed in an enteric polymer and further comprising an estrogen |
US20100040671A1 (en) * | 2008-08-12 | 2010-02-18 | Ahmed Salah U | Intravaginal Devices With a Rigid Support, Methods of Making, and Uses Thereof |
US8419793B2 (en) * | 2008-09-19 | 2013-04-16 | Mentor Worldwide Llc | Coating with antimicrobial agents |
US8420153B2 (en) * | 2008-09-19 | 2013-04-16 | Mentor Worldwide Llc | Coating with antimicrobial agents |
EP2391369A1 (en) * | 2009-01-26 | 2011-12-07 | Nitec Pharma AG | Delayed-release glucocorticoid treatment of asthma |
WO2011138689A2 (en) * | 2010-05-03 | 2011-11-10 | Izhar Halahmi | Releasing device for administering a bio-active agent |
US8580294B2 (en) | 2010-10-19 | 2013-11-12 | International Partnership For Microbicides | Platinum-catalyzed intravaginal rings |
US10137031B2 (en) | 2013-11-14 | 2018-11-27 | International Partnership For Microbicides, Inc. | Combination therapy intravaginal rings |
WO2015198104A1 (es) * | 2014-06-28 | 2015-12-30 | Laboratorios Andromaco S.A. | Pesario de cerclaje que contiene progesterona de liberación prolongada, sostenida y continua, útil para la prevención de parto prematuro |
ES2756301T3 (es) | 2014-08-19 | 2020-04-27 | Univ California | Implantes de administración localizada de fármacos y métodos de uso de los mismos |
US11338119B2 (en) * | 2020-03-20 | 2022-05-24 | The Regents Of The University Of California | Implantable drug delivery devices for localized drug delivery |
US11173291B2 (en) * | 2020-03-20 | 2021-11-16 | The Regents Of The University Of California | Implantable drug delivery devices for localized drug delivery |
US11344526B2 (en) | 2020-03-20 | 2022-05-31 | The Regents Of The University Of California | Implantable drug delivery devices for localized drug delivery |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3279996A (en) * | 1962-08-28 | 1966-10-18 | Jr David M Long | Polysiloxane carrier for controlled release of drugs and other agents |
US3545439A (en) * | 1968-01-04 | 1970-12-08 | Upjohn Co | Medicated devices and methods |
US3920805A (en) * | 1971-12-09 | 1975-11-18 | Upjohn Co | Pharmaceutical devices and method |
-
1974
- 1974-09-24 DE DE19742445971 patent/DE2445971A1/de active Pending
-
1975
- 1975-08-27 IN IN1660/CAL/75A patent/IN142359B/en unknown
- 1975-09-10 EG EG540/75A patent/EG11859A/xx active
- 1975-09-12 IL IL48100A patent/IL48100A/xx unknown
- 1975-09-15 BG BG030981A patent/BG27880A3/xx unknown
- 1975-09-18 IE IE2049/75A patent/IE41717B1/en unknown
- 1975-09-22 AT AT724275A patent/AT347588B/de not_active IP Right Cessation
- 1975-09-22 DD DD188480A patent/DD122197A5/xx unknown
- 1975-09-22 AU AU85064/75A patent/AU498204B2/en not_active Expired
- 1975-09-23 IT IT27536/75A patent/IT1042731B/it active
- 1975-09-23 US US05/616,001 patent/US4012497A/en not_active Expired - Lifetime
- 1975-09-23 HU HU75SCHE537A patent/HU175675B/hu unknown
- 1975-09-23 FI FI752660A patent/FI58871C/fi not_active IP Right Cessation
- 1975-09-23 NO NO753230A patent/NO753230L/no unknown
- 1975-09-23 ES ES441203A patent/ES441203A1/es not_active Expired
- 1975-09-23 CH CH1229875A patent/CH624580A5/de not_active IP Right Cessation
- 1975-09-23 GB GB38945/75A patent/GB1521505A/en not_active Expired
- 1975-09-23 SE SE7510658A patent/SE7510658L/xx unknown
- 1975-09-23 SU SU752174604A patent/SU605547A3/ru active
- 1975-09-24 BE BE160326A patent/BE833762A/xx unknown
- 1975-09-24 DK DK428175A patent/DK143384C/da active
- 1975-09-24 PL PL1975183556A patent/PL105375B1/pl unknown
- 1975-09-24 NL NL7511244A patent/NL7511244A/xx not_active Application Discontinuation
- 1975-09-24 ZA ZA00756082A patent/ZA756082B/xx unknown
- 1975-09-24 FR FR7529205A patent/FR2285895A1/fr active Granted
- 1975-09-24 CA CA236,245A patent/CA1049408A/en not_active Expired
- 1975-09-25 JP JP50115955A patent/JPS5161618A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
IN142359B (da) | 1977-06-25 |
FI752660A (da) | 1976-03-25 |
FI58871C (fi) | 1981-05-11 |
IT1042731B (it) | 1980-01-30 |
IL48100A (en) | 1979-01-31 |
IL48100A0 (en) | 1975-11-25 |
EG11859A (en) | 1978-03-29 |
JPS5161618A (da) | 1976-05-28 |
FR2285895A1 (fr) | 1976-04-23 |
CH624580A5 (da) | 1981-08-14 |
IE41717L (en) | 1976-03-24 |
NL7511244A (nl) | 1976-03-26 |
AU8506475A (en) | 1977-03-31 |
CA1049408A (en) | 1979-02-27 |
PL183556A1 (en) | 1978-04-24 |
FI58871B (fi) | 1981-01-30 |
IE41717B1 (en) | 1980-03-12 |
AU498204B2 (en) | 1979-02-22 |
BE833762A (fr) | 1976-03-24 |
PL105375B1 (pl) | 1979-10-31 |
DK143384B (da) | 1981-08-17 |
US4012497A (en) | 1977-03-15 |
ES441203A1 (es) | 1977-03-16 |
DK428175A (da) | 1976-03-25 |
FR2285895B1 (da) | 1980-05-09 |
GB1521505A (en) | 1978-08-16 |
ZA756082B (en) | 1976-09-29 |
SE7510658L (sv) | 1976-03-25 |
DD122197A5 (da) | 1976-09-20 |
DK143384C (da) | 1981-12-14 |
SU605547A3 (ru) | 1978-04-30 |
AT347588B (de) | 1979-01-10 |
DE2445971A1 (de) | 1976-04-08 |
BG27880A3 (en) | 1980-01-15 |
ATA724275A (de) | 1978-05-15 |
HU175675B (hu) | 1980-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO753230L (da) | ||
US4230686A (en) | Drug excipient of silicone rubber | |
US3887699A (en) | Biodegradable polymeric article for dispensing drugs | |
US3991766A (en) | Controlled release of medicaments using polymers from glycolic acid | |
US4155991A (en) | Vaginal ring | |
KR101592615B1 (ko) | 자궁내 시스템 | |
US4012496A (en) | Vaginal ring | |
DE69003347T2 (de) | Elemente mit protrahierter Wirkstoffabgabe. | |
AU741482B2 (en) | Intravaginal drug delivery devices for the administration of testosterone and testosterone precursors | |
RU2412693C2 (ru) | Система доставки | |
JP7248614B2 (ja) | 避妊具及び関連した器具 | |
TW381024B (en) | Contraceptive composition in the form of subcutaneous implants of a matrix type and a method for producing them | |
Major et al. | Implantable drug delivery systems | |
IE42324B1 (en) | Pharmaceutical preparations containing silicone rubber | |
WO2014122563A1 (en) | An intra vaginal device, and a method of reducing the rate of diffusion of active ingredients in said intra vaginal device | |
CN100423792C (zh) | 缓释型睾丸假体及其应用 | |
PL90082B1 (da) | ||
JP2003221338A (ja) | 子宮腺筋症治療製剤 | |
JPS63203610A (ja) | 複数成分からなるインプラント用の持効性医薬製剤 | |
McConville | Ian Major1, Sarah Lastakchi2, Maurice Dalton1 and | |
WO2006026844A1 (en) | Hormone delayed release composition on the basis of polyorganosiloxanes or ethylene vinyl acetate resp. process for its manufacture | |
CN116726370A (zh) | 聚合物微针、微针片及递送系统、制备方法、应用 | |
WO2020229733A1 (en) | Controlled release device for oral cavity | |
Nanjwade et al. | SILICON BASED DRUG DELIVERY SYSTEM | |
Alashetty | Histopathological Changes At Subdermal Region Due To Subdermal Biodegradable Polymer Implant An Experimental Study |